Skip to content


Aptamer Group > Applications > Therapeutics

Novel solutions to enable next-generation therapeutics

Optimer® therapeutics. Optimised for health.

Targeted delivery vehicles for future-ready therapeutics

Optimer®-drug conjugates offer highly specific targeting vehicles for the delivery of therapeutic agents to specific cell populations and tissues for the treatment of disease.

The ability to identify Optimer® that discriminate between cell types, including organ-specific and healthy vs diseased cell populations, allows for site-specific therapeutic targeting and delivery.

Optimer® can be used to deliver a wide variety of cargo and toxic payloads, including:

  • chemotherapeutic agents
  • siRNA
  • synthetic virions
  • synthetic genes.

As the discovery library can be prepared with the drug and linker conjugate in place, we are able to develop for Optimer® binders with the drug in situ, to ensure optimal stability and performance of the end-stage therapeutic.

Key benefits of Optimer®-drug conjugates

  • High tumour uptake: small molecular size of Optimer® allows improved tissue penetration
  • Optimised formatting and modification: site-specific functionalisation with a variety of linker types and excellent tox profile
  • Security of supply: Synthetic production processes simplifies Optimer®-drug conjugate development
  • Inert format: Optimer® are non-immunogenic and do not require humanisation
  • Selective cell/tissue targeting: biodistribution flexibility and reduced off-target effects

Optimer® therapeutics are next-generation aptamers that are being applied to all stages of drug discovery and development. Optimer® can act as agonists, antagonists or cell-type-specific targeting moieties for the delivery of therapeutic agents to target cells and tissues in the treatment of disease. Selected via our proprietary platforms for rapid generation and simple, consistent large-scale production, these novel therapeutics show potential to accelerate discovery and development for a wide range of human diseases.

We are working with commercial and academic partners to develop novel therapeutics for many intractable targets and to improve upon current treatments with the application of Optimer® technology.

Start your next project with Aptamer Group

Contact one of our experts today